RAAS抑制剂用于冠心病防治:优选ACEI还是ARB?  

The use of renin-angiotensin-aldosterone system inhibitors in coronary artery disease:ACEI or ARB?

作　　者：徐奕 李自成[1] XU Yi;LI Zicheng(Department of Cardiology, the First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong, China)

机构地区：[1]暨南大学附属第一医院心血管内科,广东广州510630

出　　处：《暨南大学学报（自然科学与医学版）》2022年第3期276-283,共8页Journal of Jinan University(Natural Science & Medicine Edition)

基　　金：中央高校基本科研业务费专项资金项目(21621051)。

摘　　要：肾素-血管紧张素-醛固酮系统(RAAS)抑制剂,如血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体拮抗剂(ARB)不仅被广泛用于降压治疗,在冠心病的防治中也发挥着重要的作用。但ACEI和ARB这两类药物在冠心病防治中愈合区别以及优选哪一种,仍是临床所关注的热点问题。本文试对RAAS抑制剂ACEI和ARB的心血管保护作用进行归纳和总结,并对其在冠心病防治中的应用进行综述。Renin-angiotensin-aldosterone system(RAAS)inhibitors,such as angiotensin converting enzyme inhibitors(ACEI)and angiotensin receptor blockers(ARB),not only serve as hypertensive drugs,but also play an important role in prevention and treatment of coronary artery disease(CAD).What’s the difference between these two types of RAAS inhibitors and which one is preferred remains a heat topic in modern cardiology.This review sought to summarize results from studies regarding cardio-protective effect of ACEI and ARB,and their application in prevention and treatment of CAD was reviewed.

关 键 词：冠状动脉粥样硬化性心脏病 肾素-血管紧张素-醛固酮系统 血管紧张素转换酶抑制剂 血管紧张素受体拮抗剂 

分 类 号：R541.4[医药卫生—心血管疾病]